Skip to main content

NewAmsterdam Pharma Co N.V.

NAMSW
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001936258

In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $28.1M in total; no superinvestor holds it.

Other share classesNAMS

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by NewAmsterdam Pharma Co N.V. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $226.5K in total
Open-market sells
3 filings
3 insiders, $6.59M in total
Insiders trading
4
Net value
−$6.36M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for NewAmsterdam Pharma Co N.V., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for NewAmsterdam Pharma Co N.V.
NameTitleLast reported holdingLast filingFilings, past year
Davidson Michael H.Chief Executive Officer792,923Sep 15, 20264
Smither John WDirector8,760Sep 9, 20262
Gunning Robert WilliamVice President, Controller3,200Sep 3, 20261
Kastelein Johannes Jacob PieterChief Scientific Officer69,302IndirectAug 25, 20264
Kooij Louise FrederikaChief Accounting Officer24,353Jul 22, 20267
Lange Louis GDirector10,360Mar 12, 20263
Somaiya Mayur IanChief Financial Officer58,382Jan 22, 20262
Lewis WilliamDirector10,360Jan 9, 20261
Gulfo Adele M.Director14,260Jan 9, 20261
McKenna Mark C.Director10,360Jan 9, 20261
van der Kamp Hilde JohannaDirector10,360Jan 9, 20261
Topper James NDirector3,028,524IndirectSep 17, 20250
Kling Douglas FChief Operating Officer44,000Jul 17, 20250
Marino Michael F IIISee Remarks55,000Jun 3, 20250
Audet Juliette BerangereSee Remarks15,104May 2, 20250
Jones William A JrChief Commercial Officer43,000Jan 7, 20250
Forbion Capital Fund IV Cooperatief U.A.10% Owner10,656,172IndirectJan 2, 20250
Forbion Growth Opportunities Fund I Cooperatief U.A.10% Owner10,656,172IndirectJan 2, 20250
Forbion Growth Management B.V.10% Owner10,656,172IndirectJan 2, 20250
Forbion IV Management B.V.10% Owner10,656,172IndirectJan 2, 20250
ForGrowth NAP B.V.10% Owner10,656,172IndirectJan 2, 20250
BCIP Life Sciences Associates, LP10% Owner–Dec 17, 20240
Bain Capital Life Sciences Investors, LLC10% Owner–Dec 17, 20240
Bain Capital Life Sciences Fund II, L.P.10% Owner–Dec 17, 20240
Bain Capital Life Sciences Investors II, LLC10% Owner–Dec 17, 20240
BCLS II Investco, LP10% Owner–Dec 17, 20240
BCLS II Investco (GP), LLC10% Owner–Dec 17, 20240
Bain Capital Life Sciences Fund III, L.P.10% Owner–Dec 17, 20240
BCLS Fund III Investments GP, LLC10% Owner–Dec 17, 20240
Bain Capital Life Sciences III General Partner, LLC10% Owner–Dec 17, 20240
BCLS Fund III Investments, LP10% Owner–Dec 17, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 15, 2026 (view filing)4:30 PM ETSep 141 dayDavidson Michael H.Chief Executive OfficerPPurchase+10.0K$22.65+$226.5K+1.3%792.9K after
Sep 9, 2026 (view filing)4:30 PM ETSep 45 daysSmither John WDirectorSSale−1.60K$25.32−$40.5K−15.4%8.76K after
Aug 25, 2026 (view filing)4:30 PM ETAug 241 dayKastelein Johannes Jacob PieterChief Scientific OfficerSSale−125.0K$26.91−$3.36M−64.3%69.3K after10b5-1
Jul 22, 2026 (view filing)4:05 PM ETJul 202 daysKooij Louise FrederikaChief Accounting OfficerSSale−105.0K$30.34−$3.19M−81.2%24.4K after3 lots10b5-1
Jun 24, 2026 (view filing)Jun 222 daysKooij Louise FrederikaChief Accounting OfficerSSale−40.0K$30.20−$1.21M−62.2%24.4K after2 lots10b5-1
May 27, 2026 (view filing)May 261 dayKooij Louise FrederikaChief Accounting OfficerSSale−65.0K$35.69−$2.32M−72.7%24.4K after10b5-1
Mar 12, 2026 (view filing)Mar 111 dayLange Louis GDirectorSSale−44.6K$30.42−$1.36M−81.2%10.4K after2 lots
Mar 10, 2026 (view filing)Mar 64 daysLange Louis GDirectorSSale−28.2K$29.41−$829.0K−100.0%0 after
Mar 9, 2026 (view filing)Mar 5-94 daysKastelein Johannes Jacob PieterChief Scientific OfficerSSale−300.0K$30.30−$9.09M−81.2%69.3K after3 lots10b5-1
Mar 2, 2026 (view filing)Mar 2Same dayDavidson Michael H.Chief Executive OfficerSSale−443.7K$33.25−$14.8M−71.8%174.1K after
Feb 26, 2026 (view filing)Feb 24-262 daysDavidson Michael H.Chief Executive OfficerSSale−306.3K$34.53−$10.6M−63.8%174.1K after7 lots10b5-1
Feb 24, 2026 (view filing)Feb 204 daysKastelein Johannes Jacob PieterChief Scientific OfficerSSale−45.5K$35.31−$1.61M−45.9%53.5K after2 lots
Jan 29, 2026 (view filing)Jan 27-282 daysKooij Louise FrederikaChief Accounting OfficerSSale−72.4K$32.25−$2.34M−74.8%24.4K after2 lots10b5-1
Jan 27, 2026 (view filing)Jan 23-264 daysKooij Louise FrederikaChief Accounting OfficerSSale−72.6K$33.29−$2.42M−74.9%24.4K after4 lots10b5-1
Jan 22, 2026 (view filing)Jan 20-212 daysSomaiya Mayur IanChief Financial OfficerSSale−100.0K$32.61−$3.26M−63.1%58.4K after5 lots10b5-1
Jan 9, 2026 (view filing)Jan 72 daysDavidson Michael H.Chief Executive OfficerSSale−11.6K––−3.0%378.9K after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysKastelein Johannes Jacob PieterChief Scientific OfficerSSale−6.00K$33.25−$199.5K−7.5%73.5K after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysKooij Louise FrederikaChief Accounting OfficerSSale−2.65K$33.25−$88.0K−17.6%12.4K after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysSomaiya Mayur IanChief Financial OfficerSSale−5.12K$33.25−$170.2K−13.5%32.9K after10b5-1
Dec 29, 2025 (view filing)Dec 23-266 daysKooij Louise FrederikaChief Accounting OfficerSSale−145.0K$35.84−$5.20M−90.6%15.0K after3 lots10b5-1
Sep 17, 2025 (view filing)Sep 152 daysTopper James NDirectorPPurchase+660$23.70+$15.6K0.0%3.03M after
Sep 10, 2025 (view filing)Sep 82 daysTopper James NDirectorPPurchase+1.26K$24.99+$31.5K0.0%3.03M after
Sep 10, 2025 (view filing)Sep 91 dayKooij Louise FrederikaChief Accounting OfficerSSale−150.0K$25.83−$3.87M−90.9%15.0K after2 lots
Sep 5, 2025 (view filing)Sep 32 daysKooij Louise FrederikaChief Accounting OfficerSSale−18.1K$25.09−$453.5K−54.6%15.0K after
Aug 27, 2025 (view filing)Aug 252 daysKooij Louise FrederikaChief Accounting OfficerSSale−8.27K$24.86−$205.6K−35.5%15.0K after
Aug 25, 2025 (view filing)Aug 21-224 daysKastelein Johannes Jacob PieterChief Scientific OfficerSSale−100.0K$24.72−$2.47M−59.1%69.3K after3 lots
Aug 13, 2025 (view filing)Aug 112 daysTopper James NDirectorPPurchase+471$23.98+$11.3K0.0%3.03M after
Jul 17, 2025 (view filing)Jul 15-162 daysKling Douglas FChief Operating OfficerSSale−98.6K$21.26−$2.10M−69.1%44.0K after3 lots10b5-1
Jun 26, 2025 (view filing)Jun 24-252 daysTopper James NDirectorPPurchase+3.78K$18.37+$69.5K+0.1%3.03M after2 lots
Jun 18, 2025 (view filing)Jun 162 daysTopper James NDirectorPPurchase+8.58K$19.50+$167.4K+0.3%3.02M after
Jun 18, 2025 (view filing)Jun 162 daysKling Douglas FChief Operating OfficerSSale−100.0K$19.29−$1.93M−69.4%44.0K after2 lots10b5-1
May 19, 2025 (view filing)May 154 daysKling Douglas FChief Operating OfficerSSale−100.0K––−69.4%44.0K after10b5-1
Apr 17, 2025 (view filing)Apr 152 daysKling Douglas FChief Operating OfficerSSale−100.0K––−69.4%44.0K after2 lots10b5-1
Mar 28, 2025 (view filing)Mar 262 daysTopper James NDirectorPPurchase+1.14K$22.49+$25.5K0.0%3.01M after
Mar 28, 2025 (view filing)Mar 262 daysKling Douglas FChief Operating OfficerSSale−16.5K––−27.3%44.0K after
Mar 28, 2025 (view filing)Mar 262 daysDavidson Michael H.Chief Executive OfficerSSale−12.3K––−3.0%390.4K after
Mar 19, 2025 (view filing)Mar 172 daysKling Douglas FChief Operating OfficerSSale−100.0K––−69.4%44.0K after10b5-1
Mar 6, 2025 (view filing)Mar 42 daysTopper James NDirectorPPurchase+4.00K$21.02+$84.2K+0.1%3.01M after
Mar 5, 2025 (view filing)Mar 41 dayKooij Louise FrederikaChief Accounting OfficerSSale−150.0K$20.37−$3.06M−90.9%15.0K after
Feb 20, 2025 (view filing)Feb 18-192 daysKling Douglas FChief Operating OfficerSSale−100.0K––−69.4%44.0K after2 lots10b5-1
Jan 31, 2025 (view filing)Jan 29-302 daysKling Douglas FChief Operating OfficerSSale−70.4K––−61.6%44.0K after3 lots10b5-1
Jan 29, 2025 (view filing)Jan 27-282 daysSomaiya Mayur IanChief Financial OfficerSSale−61.9K––−62.0%38.0K after4 lots10b5-1
Jan 29, 2025 (view filing)Jan 27-282 daysKling Douglas FChief Operating OfficerSSale−129.6K––−74.6%44.0K after4 lots10b5-1
Jan 2, 2025 (view filing)4:15 PM ETDec 30, 20243 daysForbion Capital Fund IV Cooperatief U.A. and 4 others10% OwnerSSale−29.8K$25.54−$762.2K−0.3%10.7M after10b5-1
Dec 30, 2024 (view filing)4:15 PM ETDec 26-274 daysForbion Capital Fund IV Cooperatief U.A. and 4 others10% OwnerSSale−74.9K$25.98−$1.95M−0.7%10.7M after2 lots10b5-1
Dec 26, 2024 (view filing)4:15 PM ETDec 20-246 daysForbion Capital Fund IV Cooperatief U.A. and 4 others10% OwnerSSale−91.1K$25.58−$2.33M−0.8%10.8M after4 lots10b5-1
Dec 20, 2024 (view filing)4:25 PM ETDec 18-192 daysForbion Capital Fund IV Cooperatief U.A. and 4 others10% OwnerSSale−157.2K$25.86−$4.07M−1.4%10.9M after3 lots10b5-1
Dec 18, 2024 (view filing)4:15 PM ETDec 16-172 daysForbion Capital Fund IV Cooperatief U.A. and 4 others10% OwnerSSale−115.5K$25.95−$3.00M−1.0%11.0M after3 lots10b5-1
Dec 17, 2024 (view filing)5:05 PM ETDec 134 daysBCIP Life Sciences Associates, LP and 9 others10% OwnerPPurchase+1.63M$24.50+$40.0M–1.63M afterDerivative
Dec 16, 2024 (view filing)4:15 PM ETDec 12-134 daysForbion Capital Fund IV Cooperatief U.A. and 4 others10% OwnerSSale−191.8K$25.34−$4.86M−1.7%11.1M after3 lots10b5-1